View in EDS

A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma.

Saved in:
Bibliographic Details
Title: A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma.
Authors: Chen GL; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Guo Y; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Yang Y; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Sang Y; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Sun S; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Liu X; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Zhou X; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Sheng CY; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., He X; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Wang J; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China., Shi R; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China., Wang Y; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China., Ji Q; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China., Ji D; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. jid09@fudan.edu.cn.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. jid09@fudan.edu.cn.
Source: NPJ precision oncology [NPJ Precis Oncol] 2026 May 13. Date of Electronic Publication: 2026 May 13.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42129335
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chen+GL%22">Chen GL</searchLink>; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Guo+Y%22">Guo Y</searchLink>; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Yang+Y%22">Yang Y</searchLink>; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Sang+Y%22">Sang Y</searchLink>; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Sun+S%22">Sun S</searchLink>; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Liu+X%22">Liu X</searchLink>; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Zhou+X%22">Zhou X</searchLink>; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Sheng+CY%22">Sheng CY</searchLink>; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22He+X%22">He X</searchLink>; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Shi+R%22">Shi R</searchLink>; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Ji+Q%22">Ji Q</searchLink>; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Ji+D%22">Ji D</searchLink>; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. jid09@fudan.edu.cn.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. jid09@fudan.edu.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101708166%22">NPJ precision oncology</searchLink> [NPJ Precis Oncol] 2026 May 13. <i>Date of Electronic Publication: </i>2026 May 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Nature%22">Springer Nature </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101708166 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2397-768X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222397768X%22">2397768X </searchLink><i>NLM ISO Abbreviation: </i>NPJ Precis Oncol
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42129335
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41698-026-01463-5
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chen GL
      – PersonEntity:
          Name:
            NameFull: Guo Y
      – PersonEntity:
          Name:
            NameFull: Yang Y
      – PersonEntity:
          Name:
            NameFull: Sang Y
      – PersonEntity:
          Name:
            NameFull: Sun S
      – PersonEntity:
          Name:
            NameFull: Liu X
      – PersonEntity:
          Name:
            NameFull: Zhou X
      – PersonEntity:
          Name:
            NameFull: Sheng CY
      – PersonEntity:
          Name:
            NameFull: He X
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Shi R
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Ji Q
      – PersonEntity:
          Name:
            NameFull: Ji D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 13
              M: 05
              Text: 2026 May 13
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2397-768X
          Titles:
            – TitleFull: NPJ precision oncology
              Type: main
ResultId 1